Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4204MR)

This product GTTS-WQ4204MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ4204MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15809MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ10482MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ8102MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ12906MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ9636MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ12537MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ15765MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ13021MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW